Clinical Trial Experience With Temsirolimus in Patients With Advanced Renal Cell Carcinoma

Seminars in Oncology

Volumn 36, Issue SUPPL. 3, 2009, Pages

  Hudes, Gary R ^a   Berkenblit, Anna ^b   Feingold, Jay ^b   Atkins, Michael B ^c   Rini, Brian I ^d   Dutcher, Janice ^e  

^a FOX CHASE CANCER CENTER   (United States)

^b PFIZER INC   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d TAUSSIG CANCER INSTITUTE   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; BEVACIZUMAB; EVEROLIMUS; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADVANCED CANCER; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CELLULITIS; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIARRHEA; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG WITHDRAWAL; DYSPNEA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; INFECTION; KIDNEY CARCINOMA; LYMPHOCYTOPENIA; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; KIDNEY NEOPLASMS; MODELS, BIOLOGICAL; PROTEIN KINASES; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 72049097131     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2009.10.013     Document Type: Article

References (56)

1. American Cancer Society. Cancer Facts and Figures 2009. Updated: 2009. American Cancer Society. http://www.cancer.org/downloads/STT/500809web.pdf Accessed November 3, 2009
2. Moore L.E., Wilson R.T., and Campleman S.L. Lifestyle factors, exposures, genetic susceptibility, and renal cell cancer risk: a review. Cancer Invest 23 (2005) 240-255
3. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer V.2.2010. Updated October 30, 2009. National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf Accessed November 3, 2009
4. Cohen H.T., and McGovern F.J. Renal-cell carcinoma. N Engl J Med 353 (2005) 2477-2490
5. National Cancer Institute. Cancer of the kidney and renal pelvis. Updated 2009. National Cancer Institute. http://seer.cancer.gov/statfacts/html/kidrp.html Accessed November 3, 2009
6. Oudard S., George D., Medioni J., and Motzer R. Treatment options in renal cell carcinoma: past, present and future. Ann Oncol 18 suppl 10 (2007) x25-x31
7. Sosman J.A. Improving outcomes in patients with advanced renal cell carcinoma. Expert Rev Anticancer Ther 8 (2008) 481-490
8. Motzer R.J., Mazumdar M., Bacik J., Berg W., Amsterdam A., and Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17 (1999) 2530-2540
9. Mekhail T.M., Abou-Jawde R.M., Boumerhi G., et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23 (2005) 832-841
10. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
11. Escudier B., Eisen T., Stadler W., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
12. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370 (2007) 2103-2111
13. Rini B.I., Halabi S., Rosenberg J.E., et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26 (2008) 5422-5428
14. Bjornsti M.A., and Houghton P.J. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4 (2004) 335-348
15. Guertin D.A., and Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 12 (2007) 9-22
16. Abraham R.T., and Gibbons J.J. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 13 (2007) 3109-3114
17. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
18. Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372 (2008) 449-456
19. Torisel [package insert] (2008), Wyeth Pharmaceuticals, Inc, Philadelphia, PA
20. Meric-Bernstam F., and Gonzalez-Angulo A.M. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27 (2009) 2278-2287
21. Brugarolas J. Renal-cell carcinoma-molecular pathways and therapies. N Engl J Med 356 (2007) 185-187
22. Kim W.Y., and Kaelin W.G. Role of VHL gene mutation in human cancer. J Clin Oncol 22 (2004) 4991-5004
23. Maranchie J.K., Vasselli J.R., Riss J., Bonifacino J.S., Linehan W.M., and Klausner R.D. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1 (2002) 247-255
24. Thomas G.V., Tran C., Mellinghoff I.K., et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12 (2006) 122-127
25. Patel P.H., Chadalavada R.S., Chaganti R.S., and Motzer R.J. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 12 (2006) 7215-7220
26. Brenner W., Farber G., Herget T., Lehr H.A., Hengstler J.G., and Thuroff J.W. Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int J Cancer 99 (2002) 53-57
27. Velickovic M., Delahunt B., McIver B., and Grebe S.K. Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis. Mod Pathol 15 (2002) 479-485
28. Kim H.L., Seligson D., Liu X., et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 173 (2005) 1496-1501
29. Robb V.A., Karbowniczek M., Klein-Szanto A.J., and Henske E.P. Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol 177 (2007) 346-352
30. Pantuck A.J., Seligson D.B., Klatte T., et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma. Cancer 109 (2007) 2257-2267
31. Cho D., Signoretti S., Dabora S., et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 5 (2007) 379-385
32. ClinicalTrials.gov. Updated: 2009. Bethesda, MD: US National Institutes of Health. www.clinicaltrials.gov Accessed November 3, 2009
33. Raymond E., Alexandre J., Faivre S., et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22 (2004) 2336-2347
34. Hidalgo M., Buckner J.C., Erlichman C., et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 12 (2006) 5755-5763
35. Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (2004) 909-918
36. Motzer R.J., Bacik J., Murphy B.A., Russo P., and Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20 (2002) 289-296
37. Motzer R.J., Hudes G.R., Curti B.D., et al. Temsirolimus plus interferon alfa phase I trial in patients with advanced renal cell carcinoma. J Clin Oncol 25 (2007) 3958-3964
38. Bellmunt J., Szczylik C., Feingold J., Strahs A., and Berkenblit A. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 19 (2008) 1387-1392
39. de Souza P., Maart K., Laurell A., et al. Results of a phase 3, randomized study of patients with advanced renal cell carcinoma (RCC) and poor prognostic features treated with temsirolimus, interferon-α, or the combination of temsirolimus and interferon-α [abstract 4-M181]. Eur J Cancer Suppl (2007) 5
40. Parasuraman S., Hudes G., Levy D.E., et al. Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon-a (IFN) or the combination of IFN + TEMSR [abstract 5049]. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 25 suppl 18S (2007) 247s
41. Logan T., McDermott D., Dutcher J., et al. Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features [abstract 5050]. J Clin Oncol, 2008 ASCO Annual Meeting Proceedings 26 part I suppl 15S (2008) 262s
42. Dutcher J.P., de Souza P., McDermott C., et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 26 (2009) 202-209
43. Kapoor A., and Figlin R.A. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. Cancer 115 (2009) 3618-3630
44. Clinicaltrials.gov identifier: NCT00474786. A randomized trial of temsirolimus versus sorafenib as second-line therapy in patients with advanced renal cell carcinoma who have failed first-line sunitinib therapy. Updated 2009. US National Institutes of Health. http://www.clinicaltrials.gov/ct2/show/NCT00474786 Accessed November 3, 2009
45. Motzer R.J., Bacik J., Schwartz L.H., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 (2004) 454-463
46. Sosman J.A., Puzanov I., and Atkins M.B. Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res 13 (2007) 764s-769s
47. Patnaik A., Ricart A., Cooper J., et al. A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies [abstract 3512]. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 25 suppl 18S (2007) 141s
48. Patel P.H., Senico P.L., Curiel R.E., and Motzer R.J. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 7 (2009) 24-27
49. Merchan J.R., Liu G., Fitch T., et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results [abstract 5034]. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 25 part I suppl 18S (2007) 243s
50. Merchan J.R., Pitot H.C., Qin R., et al. Phase I/II trial of CCI-779 and bevacizumab in advanced renal cell carcinoma (RCC): safety and activity in RTKI refractory RCC patients [abstract 5039]. J Clin Oncol, 2009 ASCO Annual Meeting Proceedings 27 suppl 15s (2009) 244s
51. Clinicaltrials.gov identifier: NCT00112840. CCI-779 and bevacizumab in treating patients with metastatic or unresectable kidney cancer. Updated 2009. US National Institutes of Health. http://www.clinicaltrials.gov/ct2/show/NCT00112840 Accessed November 3, 2009
52. Clinicaltrials.gov identifier: NCT00378703. The BeST trial: a randomized phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy (CTT) with bevacizumab, sorafenib and temsirolimus in advanced renal cell carcinoma. Updated 2009. US National Institutes of Health. http://www.clinicaltrials.gov/ct2/show/NCT00378703 Accessed November 3, 2009
53. Clinicaltrials.gov identifier: NCT00619268. Combination of temsirolimus and bevacizumab in patient with metastatic renal cell carcinoma (TORAVA). Updated 2009. US National Institutes of Health. http://www.clinicaltrials.gov/ct2/show/NCT00619268 Accessed November 3, 2009
54. Clinicaltrials.gov identifier: NCT00631371. Phase 3b, randomized, open-label study of bevacizumab (Avastin) + temsirolimus (Torisel) vs. bevacizumab (Avastin) + interferon-alfa (Roferon) as first-line treatment in subjects with advanced renal cell carcinoma. Updated 2009. US National Institutes of Health. http://www.clinicaltrials.gov/ct2/show/NCT00631371 Accessed November 3, 2009
55. Clinicaltrials.gov identifier: NCT00782275. Avastin and temsirolimus following tyrosine kinase inhibitor failure in patients with advanced renal cell carcinoma. Updated 2009. US National Institutes of Health. http://www.clinicaltrials.gov/ct2/show/NCT00782275 Accessed November 3, 2009
56. Clinicaltrials.gov identifier: NCT00979966. Study in non-clear renal carcinoma (Ncc-RCC) temsirolimus versus sunitinib. Updated 2009. US National Institutes of Health. http://www.clinicaltrials.gov/ct2/show/NCT00979966 Accessed November 3, 2009